To Explore the Application Value of Magnetic Resonance Imaging in Noninvasive Quantitative Evaluation of Graft Function and Systemic Metabolism After Renal Transplantation
1 other identifier
observational
500
0 countries
N/A
Brief Summary
At present, renal biopsy is the gold standard for evaluating the pathology of renal transplants, but it is invasive and has the risk of serious complications; and the sampled tissue is only a small part of the kidney, which is prone to sampling bias and lacks reliable and comprehensive detection results. Therefore, it is an urgent problem to develop a non-invasive dynamic detection method for renal insufficiency and transplanted kidney. With the continuous development and updating of technology, imaging provides a new way for non-invasive evaluation of renal allograft pathology including rejection reaction, acute renal allograft injury, viral infection, etc. MRI technology has developed the diagnosis of renal allograft rejection, fibrosis and other renal allograft dysfunction from macroscopic simple biomorphological changes to microscopic complex pathophysiological changes due to its high resolution of soft tissue and its ability to perform multi-parameter analysis. In recent years, under the background of precision medicine, artificial intelligence technologies such as radiomics and machine learning are rapidly becoming very promising auxiliary tools in the evaluation of transplanted kidney images. They can extract and learn features in images with high throughput, make greater use of information that cannot be recognized by human eyes in medical images, and realize disease diagnosis, prognosis evaluation, and curative effect prediction by establishing models. However, most of the current research is in the preliminary stage. There are few evaluation studies on kidney transplantation. It is believed that with the continuous improvement of algorithms and optimization of models, radiomics and machine learning will make great progress, which will promote the development of individualized and precise medicine for patients with renal insufficiency to a certain extent.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2025
CompletedFirst Posted
Study publicly available on registry
August 28, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 12, 2031
August 28, 2025
August 1, 2025
5.3 years
August 21, 2025
August 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
ESKD
The patient reaches CKD stage 5 and the glomerular filtration rate is less than 15 ml/min
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Study Arms (1)
renal allograft patients
renal allograft patients
Eligibility Criteria
renal allograft patients
You may qualify if:
- (1) Patients with MR examination after kidney transplantation;
- (2) Age/gender: unlimited;
- (3) Patients who voluntarily participate in clinical trials and sign written subject informed consent
You may not qualify if:
- \- (1) Patients with pacemakers, unknown materials, metal implants, neurostimulators, claustrophobia, etc.
- (2) Patients who cannot tolerate adequate breath-holding for adequate MR examination;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 21, 2025
First Posted
August 28, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
December 30, 2030
Study Completion (Estimated)
December 12, 2031
Last Updated
August 28, 2025
Record last verified: 2025-08